Clinical Trial Update: A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M [Phase 2]

View source ↗

Summary

Phase 2 study evaluating malaria vaccines R78C and RH5.1 with the Matrix-M adjuvant, in combination with R21/Matrix-M, is currently active but not recruiting. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Falciparum Malaria
• Malaria

Drugs mentioned

• Matrix-M (Matrix-M adjuvant)
• R21/Matrix-M
• R78C (R78C malaria antigen)
• RH5.1 (RH5.1 malaria antigen)

Snippet

Sponsor: University of Oxford | Conditions: Malaria,Falciparum | Phase 2 | Status: ACTIVE_NOT_RECRUITING